Six Days of VA-ECMO Support for Combined Respiratory and Cardiac Failure

The first clinical case using the Lifemotion® ECMO system has been successfully completed at Mersin University Hospital, marking an important milestone in the introduction of the platform in Türkiye.

Mersin University Hospital is an academic referral center serving a broad regional population, with a central role in advanced critical care and cardiovascular services. The introduction of a new extracorporeal life support system in such an environment requires formal protocol review, technical validation, and coordinated readiness across anesthesiology, perfusion, intensive care, and cardiovascular teams — including alignment with institutional treatment protocols, familiarization with monitoring and alarm systems, and structured observation during early implementation.

The successful execution of this first case reflects that preparation and the collaborative effort of the teams involved.

Clinical Overview

The patient required veno-arterial extracorporeal membrane oxygenation (VA-ECMO) due to combined respiratory failure and cardiac support needs secondary to aortic insufficiency.

Extracorporeal support was maintained for six days, during which hemodynamic stability and gas exchange were continuously monitored and managed in accordance with institutional standards of care.

Following progressive clinical improvement, the patient was successfully weaned from extracorporeal support and recovered.

Clinical Leadership

This case was pionnered by Professor Handan Birbiçer, Head of the Anesthesiology and Reanimation Department. Professor Davud Yapıcı, intensive care specialist, also played a crucial role in the succesful completion of the
first procedure.

Introducing a new ECMO system requires experienced clinical oversight, particularly during early adoption when teams are integrating new monitoring interfaces, operational workflows, and safety checks into established extracorporeal support practice.

Professor Birbicer coordinated the multidisciplinary effort, ensuring structured implementation and patient-centered management throughout the six-day support period.

The successful completion of this VA-ECMO case represents an important step in the broader introduction of the Lifemotion® ECMO system in Türkiye.

First clinical applications provide the foundation for ongoing institutional experience, team familiarity and procedural refinement, structured post-case review, and integration into routine clinical practice where appropriate.

As further clinical experience is gathered, additional insights may emerge regarding workflow integration, operational efficiency, and clinical familiarity within established ECMO programs. For now, the successful six-day support and patient recovery mark a meaningful first milestone.

The post First Clinical Use of the Lifemotion® ECMO System at Mersin University Hospital, Türkiye appeared first on Lifemotion.

Daniela brings extensive international expertise in ECMO and life support technology, with experience spanning the entire product journey—from early prototyping to global launch and adoption. She has worked closely with clinicians, R&D teams, and commercial operations, giving her a true 360° perspective on what it takes to bring innovation from concept to bedside.

To mark her arrival, we asked Daniela a few questions about her vision for Lifemotion and what inspires her in her work.

What attracted you to Lifemotion and to the opportunity of leading Global Product Management?
“I identified Lifemotion as a dynamic and fast-growing company. This role allows me to contribute to meaningful innovation while also challenging myself in a new environment. Expanding Lifemotion’s global footprint and strengthening our portfolio to improve patient care worldwide is a mission that inspires me every day.”

From your perspective, what are the most important priorities for Lifemotion’s product strategy right now?
“The key priorities are to fine-tune and consolidate our current, highly reliable product portfolio, and to expand the Lifemotion brand. This means strengthening our presence in existing markets while also entering new ones, spreading these advanced solutions globally to improve patient care everywhere.”

How do you see your role contributing to innovation and adoption of ECMO technology worldwide?
“My previous global role gave me a 360-degree view of the entire product lifecycle—from prototyping to full market release and the commercial strategies needed for market penetration. Having also worked within manufacturing, I gained a deep understanding of the internal processes required to bring projects to fruition. This background, combined with daily collaboration with clinicians and internal teams, enables me to manage product lines comprehensively, balancing new product development with market strategy.”

What will be your focus in connecting clinical needs, product development, and market expansion?
“My main focus is to guide and actively contribute to the development of products that fully meet customer needs. The ultimate goal is to generate revenue while creating reliable and effective solutions for patient care.”

On a personal note, what inspires you in your work, and what keeps you motivated outside the office?
“What inspires me most is building strong, synergistic relationships with my manager and colleagues. Quality relationships make all the difference. I am also motivated by being part of a company that is flexible, values my input, provides opportunities for growth, and trusts me with autonomy to act in alignment with company goals.”

We are excited to welcome Daniela to Lifemotion headquarters in Shenzhen and look forward to her leadership in advancing the Lifemotion portfolio worldwide.

The post Lifemotion Welcomes Daniela Reboli as Director of Global Product Management appeared first on Lifemotion.

ECPR and Dual Mechanical Circulatory Support in a 66-Year-Old Male

Following their initial successful experience earlier this year, the mechanical circulatory support (MCS) team at Universitätsmedizin Frankfurt has now reported another complex case using the Lifemotion® ECMO system, this time in a high-acuity extracorporeal cardiopulmonary resuscitation (ECPR) and dual mechanical circulatory support (ECMELLA) setting.

A 66-year-old male was referred to the Intensive Care Unit (ICU) with severe lactic acidosis, most likely secondary to cardiogenic shock. Shortly after admission, he suffered cardiac arrest. The ECPR team was activated immediately, and bi-femoral veno-arterial extracorporeal life support (ECLS) was initiated using the Lifemotion® system. Time from arrest to initiation of extracorporeal circulation was under 12 minutes, enabling rapid hemodynamic stabilization.

System Setup and Workflow

ECLS was established via bi-femoral cannulation in a veno-arterial configuration, with left ventricular unloading achieved through a micro-axial pump, creating a combined ECMELLA configuration.

The Lifemotion® system performed reliably throughout all phases of support and transport, with no technical or disposable-related issues reported. The ICU and perfusion teams noted smooth handling, stable flow performance, and seamless adaptation during critical workflow transitions.

Transport Path and Team Coordination

Over the course of care, the patient required several intra-hospital transports:

Intensive Care Unit → Radiology Department – console only

• Intensive Care Unit → Radiology Department – console only
• Intensive Care Unit → Catheterization Laboratory – entire sprinter unit, return as ECMELLA
• Intensive Care Unit → Operating Room – entire sprinter unit

Each transfer was conducted by a coordinated team including an intensive care physician, ICU nurse, and perfusionist.

All destinations were located within the same hospital complex but on different floors, with route planning and communication minimizing transfer time and patient risk.

From a clinical perspective, the team emphasized that transport configuration plays a critical role in maintaining system stability and patient safety. While console-only transport can be suitable for short transfers (such as to CT), longer or procedure-based transports often benefit from keeping the entire sprinter unit intact. This approach helps maintain continuous power supply, gas exchange, and temperature control, and provides greater physical stability when positioning the system around procedure tables or narrow hospital pathways.

As the perfusion team noted, “In daily practice, the practical mobility of the complete sprinter unit can be as important as the portability of the console itself. Particularly when moving through tight spaces and procedural environments.”

Outcome and Learnings

ECLS support was maintained for five days, after which the patient was successfully weaned from extracorporeal circulation.

This case underscores the importance of system adaptability in dynamic environments such as the ICU, Radiology Department, Cath Lab, and Operating Room. The Lifemotion® system’s compact mobility and stable operation allowed the team to maintain full control even under demanding, multi-stage care conditions.

As one clinician summarized, “When going full MCS, you need a system that can handle and adapt to changing environments. Lifemotion proved up to the task.”

Conclusion

The latest case at Universitätsmedizin Frankfurt further reinforces the clinical reliability, transport capability, and operational flexibility of the Lifemotion® system. Its performance in combined ECPR and ECMELLA configuration demonstrates the system’s readiness for complex, multi-modality cardiac support scenarios.

The success of this case also reflects the close collaboration between Lifemotion® and Life Systems Medizintechnik-Service GmbH (Life Systems), the official distributor of the Lifemotion® system in Germany. Life Systems provides hospitals and clinical teams with comprehensive support in perfusion and extracorporeal life support, including product distribution, clinical training, and on-site technical expertise. This partnership ensures that teams across Germany receive not only advanced technology but also the dedicated service and know-how needed to deliver the highest standards of patient care.

“Our partnership with Life Systems represents more than technology; it is a commitment to patient care,” said Michael van Driel, VP Business Development & General Manager at Lifemotion®. “We believe that the future of ECLS and perfusion in Europe depends on equipping and empowering outstanding clinical teams like Dr. Marcus Hermann and his colleagues in Frankfurt. These professionals bring skill, collaboration, and heart to every case.”

Lifemotion® extends its sincere thanks to Dr. Marcus Hermann, PD Dr. Robert Stöhr, Dr. Lukas Probst, and the entire MCS team at Universitätsmedizin Frankfurt, as well as Life Systems Medizintechnik-Service GmbH (Life Systems) for their continued collaboration and valuable feedback supporting the advancement of ECMO technology and best practice in critical care.

All clinical details and feedback are shared with permission and in accordance with the institutional publicity policies of Universitätsmedizin Frankfurt. No personal or patient-identifiable information is included. This content is intended for professional and informational purposes only and does not replace clinical guidelines, product labeling, or instructions for use. Device use should always follow CE-marked indications and local protocols

The post Advanced Clinical Use of Lifemotion® at Universitätsmedizin Frankfurt appeared first on Lifemotion.

A milestone achievement at Bundeswehr Central Hospital Koblenz highlights the reliability and growing adoption of the Lifemotion system.

We are proud to announce the first successful clinical use of the Lifemotion ECMO system at a German military hospital: the Department of Cardiac Surgery, Bundeswehr Central Hospital (BwZKrhs) Koblenz.

On September 9, 2025, a 60-year-old patient was admitted with papillary muscle rupture of ischemic origin, COPD, and severely impaired lung function. The patient was initially stabilized using an ECMELLA configuration. After cardiac recovery, the Impella was weaned, and the treatment plan required transitioning from VVA-ECMO to VV-ECMO.

Given the extended support period (11 days) and the limited function of the existing ECMO system, the interdisciplinary team decided to perform a system change.

On September 26, 2025, the switch to VV-ECMO and transition to the Lifemotion system was carried out successfully. The procedure went smoothly, and the Lifemotion system performed reliably and without complications.

 
Clinical team at Bundeswehr Central Hospital Koblenz with the Lifemotion® ECMO system following the successful first cases. Their expertise and collaboration mark an important milestone for the adoption of Lifemotion within the German military healthcare system (September 2025).

Clinical impressions of the Lifemotion ECMO system included:

• Rapid and straightforward setup and priming process
• Clear and intuitive display with logical menu navigation
• Stable connectors and cabling for temperature, pressure, and flow
• Well-designed transport options, including strong battery capacity and the ability to operate the drive unit and battery alone during transport
• Reliable oxygenation and CO₂ elimination throughout the support period
• Transparent alarm management and clear digital overview of system status
• The team reported that the Lifemotion ECMO system left a very reliable and well-thought-out impression, with particular appreciation for its ease of use and consistent performance.
  
  

We sincerely thank the Department of Cardiac Surgery at BwZKrhs Koblenz for this important collaboration, as well as our partner Cormed — and especially Mr. Detlef Balcke — for their support, training, and expertise throughout the process.

This milestone marks the very first use of the Lifemotion ECMO system in a German military hospital, underscoring its clinical reliability and growing role in advancing extracorporeal life support across Europe.

The post First Lifemotion ECMO Case in a German Military Hospital appeared first on Lifemotion.

We are excited to welcome Laura Maglio to Lifemotion as Business Director for Europe, Middle East, and Africa.

With a Biomedical Engineering degree and Master’s in Engineering for Surgery from Politecnico di Milano, Laura brings 17+ years of specialized experience in cardiovascular technologies from her career at Medtronic, where she progressed through roles spanning clinical research, product management, and strategic marketing for cardiopulmonary systems and ECLS technologies.

Her deep expertise in ECMO and cardiovascular devices, combined with her mission-driven approach to improving patient outcomes, aligns perfectly with Lifemotion’s values of excellence, innovation, and patient-centered care. Laura’s mission-driven approach and proven track record of improving patient outcomes through strategic leadership of projects that merge medical expertise, technology, and commercial growth align perfectly with Lifemotion’s values of excellence, innovation, and patient-centered care.

Laura’s mission-driven approach and proven track record of improving patient outcomes through strategic leadership of projects that merge medical expertise, technology, and commercial growth align perfectly with Lifemotion’s values of excellence, innovation, and patient-centered care.

Connect with Laura on LinkedIn
Emai: Laura.Maglio@cbmsz.com

Laura, can you tell us a bit about your professional background and what brought you to Lifemotion?

My journey began with a Biomedical Engineering degree from Politecnico di Milano, followed by a specialized Master’s in Engineering for Surgery focusing on cardiac, neuro, and orthopedic applications. This technical foundation gave me deep insights into how engineering principles can solve complex clinical challenges. I then built my career over 15+ years at Medtronic, progressing through various roles from clinical research to product management and strategic marketing across cardiovascular technologies.

Throughout my tenure at Medtronic, I’ve worked extensively with cardiopulmonary systems, ECLS technologies, and cardiovascular devices — gaining comprehensive understanding of both the technical complexities and market dynamics in this space. My experience spans the full product lifecycle, from clinical studies to commercialization, always with teams committed to improving patient outcomes.

What brought me to Lifemotion is the perfect alignment between my cardiovascular and ECMO expertise and Lifemotion’s mission-driven approach. Having worked deeply in this field, I understand the critical importance of ECMO technology and the impact it can have on patient lives. Lifemotion’s commitment to excellence, innovation, and tangible outcomes in ECMO resonated strongly with me. Joining the team felt like a natural evolution to contribute my specialized experience while continuing to grow within a company that shares the values I care about: authenticity, collaboration, and patient-centered care.

What excites you most about your new role as Business Director EMEA?

What excites me most about this role is the opportunity to make a real impact on how advanced therapies like ECMO are brought to patients across EMEA. It’s not only about driving business growth — it’s about building bridges between clinical teams, healthcare systems, and innovation, so that more patients can benefit from life-saving technologies.

I’m particularly inspired by the chance to work with diverse professionals across different countries, learning from each context and tailoring solutions that truly meet local needs. This role gives me the privilege to combine strategic vision with hands-on collaboration, and that’s what motivates me every day.

Where do you see the biggest opportunities for Lifemotion in Europe, the Middle East, and Africa?

I see significant opportunities for Lifemotion in strengthening access to ECMO therapy across regions where awareness and infrastructure are still developing. In many parts of EMEA, there is a growing recognition of the value of ECMO in critical care — but also a clear need for education, training, and sustainable programs to make it accessible.

Another opportunity lies in collaboration: working closely with healthcare professionals, hospitals, and health systems to tailor solutions that fit local realities. By combining innovation with practical implementation, Lifemotion can help build long-term capacity and ensure that advanced life-support therapies are not only available, but also effectively integrated into patient care.

Ultimately, the opportunity is to bridge gaps — between innovation and practice, between countries with different levels of resources, and between today’s needs and tomorrow’s standards of care.

How do you plan to build strong relationships with clinical and industry partners in the region?

For me, building strong relationships starts with listening. Every clinical team and every partner has its own context, challenges, and priorities. My first step will be to understand these deeply, so that we can co-create solutions rather than imposing one-size-fits-all approaches.

At the same time, this is not new to me — in my previous role I had the privilege of working closely with physicians and clinical teams, and I’ve seen firsthand how trust and collaboration are built over time. This new chapter is not just about starting fresh relationships, but also about continuing the journey of dialogue and partnership I’ve already begun.

I also believe in transparency and consistency. Trust is earned by being reliable, following through on commitments, and creating real value in every interaction. With clinical partners, that means supporting not only with technology but also with training, education, and ongoing collaboration. In short, my approach is to build relationships that are not transactional but transformational — rooted in mutual respect and shared purpose.

On a more personal note: what motivates you in your work, and what do you enjoy outside of it?

What motivates me in my work is knowing that what we do can directly or indirectly improve patients’ lives. Working in healthcare means being part of something bigger than ourselves, and this perspective keeps me focused and inspired every day. I’m also motivated by teamwork: I firmly believe that the best results are achieved when different perspectives unite around a common goal.

Outside of work, I enjoy spending time with my family and being outdoors, whether traveling, exploring new places, or simply enjoying nature. I really enjoy painting. These moments give me balance and energy and often help me bring a new perspective to my professional life.

We’re thrilled to have Laura on board and look forward to the impact she’ll make at Lifemotion and within the broader ECMO community across EMEA. Welcome, Laura!

The post Expanding ECMO Access Across EMEA, An Interview with Laura Maglio, Lifemotion’s New Business Director EMEA appeared first on Lifemotion.

Lifemotion is proud to have supported the recent ECMO training course held on 25–26 July 2025 at Zuid-Afrikaans Hospital in Pretoria, South Africa. Conducted in partnership with our regional distribution partner, Respiratory Care Africa (RCA), the program formed part of our broader commitment to advancing extracorporeal therapy through education, collaboration, and clinical integration.

Organized by ECMO South Africa, the two-day course brought together a multidisciplinary group of healthcare professionals—including intensivists, perfusionists, nurses, and educators—for a comprehensive learning experience that combined theoretical modules with hands-on, simulation-based training. The curriculum focused on the safe and effective use of extracorporeal membrane oxygenation (ECMO) in the management of critically ill patients, with particular attention to circuit interaction and real-world application in the ICU setting.

“The scope and depth of the course were exceptional,” said Michael van Driel, International Vice President of Lifemotion.“The use of simulation and practical instruction exemplifies how ECMO training should be conducted. The work being led by Dr. Marlice van Dyk, Dr. Norbert Welkovics, and their colleagues at the Zuid-Afrikaans Hospital Education Centre reflects a deep commitment to clinical excellence and patient-centered care.”

The training sessions incorporated Lifemotion’s Lifemotion® system, offering participants the opportunity to familiarize themselves with a CE-marked, modular ECMO platform designed for seamless integration in both ICU and transport settings. The system’s mobility, intuitive interface, and real-time monitoring features contributed to a practical and effective learning environment.

This initiative underscores Lifemotion’s mission to support the global expansion of extracorporeal life support through technology, training, and strategic partnerships. By contributing to the development of local expertise, we aim to create sustainable value for clinicians, healthcare institutions, and critically ill patients worldwide.

In addition to delivering high-quality education, the course fostered professional exchange and collaboration, helping to strengthen the regional ECMO community and establish a foundation for continued capacity building across the African continent.

Lifemotion expresses sincere appreciation to Zuid-Afrikaans Hospital, ECMO SA, Respiratory Care Africa, and all participating clinicians for their dedication and engagement throughout the training. We remain committed to supporting efforts that enhance the delivery of advanced life support therapies—anywhere they are needed.

Clinical team at Zuid-Afrikaans Hospital in Pretoria engaging with the Lifemotion® ECMO system during hands-on simulation as part of the ECMO SA training course (July 2025).

The post Strengthening ECMO Capacity in South Africa: Lifemotion Supports Advanced Training at Zuid-Afrikaans Hospital appeared first on Lifemotion.

MIRANDOLA, Italy – July 28, 2025

Shared by the hospital, this image shows the Lifemotion® in active use during their first clinical case. The system’s compact design and intuitive interface support seamless bedside integration in the ICU.

The Lifemotion® is a CE-marked extracorporeal life support system featuring a modular, mobile architecture and real-time touchscreen monitoring, built for both routine and emergency ECMO workflows.

System Setup and Team Integration: Smooth Workflow and Stable Support

The Frankfurt team reported that the setup process was efficient, with no technical issues observed during the run. The interface, while unfamiliar to the staff initially, was quickly understood and successfully integrated into the unit’s established ECMO protocols.Cannulation was performed bedside by the ICU team, without the need for patient transport or any configuration changes. The short, stable duration of support meant the system was not tested at maximum operational capacity. However, it performed reliably throughout the case.

Clinical Team Feedback: A Solid Start and Room to Explore

Perfusionists and medical staff responded positively to the system’s performance. Nursing staff quickly gained confidence following onsite training and support.

The team emphasized that the system fit seamlessly into their existing ECMO routine, without causing delays or disruptions. While the short duration did not allow for an extended evaluation of long-term performance, clinicians expressed interest in using the system for future cases with longer expected runtimes. As one member of the team shared,“We plan to continue the test phase and generate as much input for Lifemotion as possible. Our goal is to better understand how the system performs over time, especially in complex and prolonged cases.”

Conclusion

The first clinical use of the Lifemotion® ECMO system at Universitätsmedizin Frankfurt was carried out safely, with positive feedback from perfusionists, ICU physicians, and nursing staff. The system’s efficient setup, smooth integration, and stable performance during this short case mark a strong start to the collaboration.

Lifemotion® extends its sincere thanks to the entire clinical team and acknowledges the valuable support of Life Systems Medizintechnik-Service GmbH.

Special recognition to: 

PD Dr. Dr. Robert Stöhr, MCS Program Director
Dr. Marcus Hermann, Chief Perfusionist
Burcu Bakir, Perfusionist (case support & staff training)

Their expertise and collaboration contribute directly to the advancement of ECMO technology and best practices in critical care.

All feedback and experiences are shared with permission and in accordance with the institutional publicity policies of Universitätsmedizin Frankfurt. No personal or patient-identifiable information is included.

This content is intended for professional and informational purposes only. It reflects individual clinician experiences and does not replace clinical guidelines, product labeling, or instructions for use. Device use should always follow CE-marked indications and local protocols.

The post First Clinical Experience with Lifemotion® at Universitätsmedizin Frankfurt appeared first on Lifemotion.

The intensive care team at University Hospital Antwerp (UZ Antwerp) in Belgium recently completed their first case using the Lifemotion® ECMO system, supporting a 65-year-old male patient with eCPR who was successfully weaned from VA-ECMO after 14 days of support. The experience provided valuable insights into the system’s usability and performance from both nursing and perfusionist perspectives

The Lifemotion® extracorporeal life support system, designed for ease of use in critical care settings. Its compact and modular design supports high-mobility applications, while the intuitive touchscreen interface provides real-time monitoring of key parameters.

Nursing Team Feedback: User-Friendly and Intuitive

ICU nurses highlighted the system’s user-friendliness, noting that the device is intuitive to operate for both experienced ECMO practitioners and colleagues new to the technology. They described the interface as logical, allowing for quick adjustment of settings and immediate visibility of critical information. The clear, concise monitor and graphical display were especially appreciated, providing a comprehensive overview of the system at a glance. Overall, the nursing team expressed widespread satisfaction, emphasizing that the Lifemotion® system’s clarity and ease of use would make it a valuable addition to their department.

Perfusionist Perspective: Solid Performance and Transport Potential

The perfusionist department observed that the oxygenator delivered a surprisingly low R-value (delta P divided by Flow), a metric closely monitored by the team as it could indicate an oxygenator changeout. Although the system was used near the patient’s weaning phase and not pushed to its operational limits, it performed very well. While no patient transport was conducted in this case, the team expressed confidence in the system’s suitability for transport scenarios, citing its comprehensive parameter overview and portability.

The perfusion team highlighted the growing importance of integrated SvO₂ and hematocrit monitoring in European tender evaluations. They noted that incorporating these capabilities would further strengthen the Lifemotion® system’s position in an increasingly competitive ECMO market and align well with evolving clinical and procurement expectations.

Conclusion

The first clinical use of the Lifemotion® ECMO system at UZ Antwerp, Belgium,  was met with positive feedback from both nursing and perfusionist teams. The device’s intuitive interface, clear visual display, and reliable performance were particularly appreciated, supporting effective care delivery in a complex case.

The insights shared by the team underscore the system’s strong clinical utility and provide valuable direction for ongoing innovation—particularly as Lifemotion continues to evolve features in line with emerging clinical needs and user priorities.

Lifemotion® extends its sincere thanks to the UZ Antwerp team for their trust, collaboration, and constructive input. Their experience contributes meaningfully to the advancement of ECMO technology and best practices in critical care.

All feedback and experiences are shared with the permission of UZ Antwerp and in accordance with the institution’s publicity policies. No personal or patient-identifiable information is included.
This content is intended for professional and informational purposes only. It reflects individual clinician experiences and does not replace clinical guidelines, product labeling, or instructions for use. Device use should always follow CE-marked indications and local protocols.

The post First Clinical Experience with Lifemotion® at UZ Antwerp  appeared first on Lifemotion.

Lifemotion announces the European launch of the Lifemotion® System following CE mark approval. The first European clinical cases were successfully completed at University Hospital of Hannover in Germany and University Hospital Virgen de la Arrixaca in Murcia, Spain, marking the system’s first use outside China, where it has supported thousands of patients.

In a landmark case in Spain, the Lifemotion® System was used for inter-hospital transport and patient retrieval, running entirely on battery power for its motor, pump, and oxygenator. This case highlights the system’s exceptional mobility and reliability in critical care transport, reinforcing its role as a game-changing solution in extracorporeal life support.

The University Hospital of Hannover—one of Europe’s most well-published and earliest adopters of respiratory support technologies—and University Hospital Virgen de la Arrixaca both praised the system for its innovative pump design, excellent gas exchange, low-pressure drop characteristics of the oxygenator, and a user interface that is intuitive and easy to operate—critical in high-pressure clinical environments.

The entire Lifemotion ECMO system has received approval for extended 14-day use including the individual components, setting the benchmark in sustained critical care support.

At both centers, clinicians praised the system’s innovative pump design, low pressure drop performance of the oxygenator, and intuitive, easy-to-use interface

“The Lifemotion® System brings a new level of flexibility and reliability to ECLS. Its compact design, seamless user interface, and ability to run on battery power made it especially effective during our patient transport case. We see great potential for this system not only in the ICU, but also in retrieval and emergency scenarios where mobility is essential,” said Dr. Juan Blanco Morillo, ECLS Care & Perfusion Unit Coordinator at University Hospital Virgen de la Arrixaca, Murcia, Spain.

To showcase these initial clinical experiences, Lifemotion will host an expert roundtable at EUROELSO 2025 in Milan on Thursday, April 24, featuring internationally renowned leaders in extracorporeal support. The panel, chaired by Dr. Heidi Dalton (ECMO specialist and pediatric intensivist, USA), Prof. Roberto Lorusso (cardiothoracic surgeon and ECLS researcher, Netherlands), and Dr. Gregory J. Schears (ECMO implementation and management expert, USA), will discuss the first European applications of the Lifemotion® System and explore its expanding clinical potential.

About Lifemotion®

Lifemotion® specializes in advanced Extracorporeal Life Support (ECLS) and critical care solutions. Headquartered in Shenzhen, China, with an international office in Mirandola, Italy—the world’s leading medical technology hub—the company combines medical expertise with advanced production capabilities. Its vertically integrated approach ensures full control over manufacturing, from component production to final assembly. Committed to innovation and operational excellence, Lifemotion® delivers life-saving solutions worldwide with uncompromising quality and reliability.

For more information, visit https://www.cbmlifemotion.com

Media Contact:

Alice Luppi
Marketing Communications Manager
Alice.Luppi@CBMsz.com

Connect with Lifemotion® :Website I LinkedIn

The post Lifemotion® System Launches in Europe with First Clinical Cases in Germany and Spain appeared first on Lifemotion.

Q: You have extensive experience in perfusion and extracorporeal support. What excites you most about joining Lifemotion?

A: Joining Lifemotion is an exciting opportunity to apply my clinical and technical expertise to help enhance extracorporeal life support solutions. Over the years, I’ve worked with advanced perfusion and ECLS technologies, contributing to their implementation and development across various clinical settings. Lifemotion’s commitment to education, innovation, and service excellence aligns perfectly with my vision of supporting the ECLS community and driving better outcomes for patients.

Q: You’ve worked across multiple countries. How have you seen ECLS evolve globally?

A: The adoption of ECLS and ECMO has grown significantly worldwide, becoming a critical life-saving therapy for diverse patient populations. It’s been inspiring to witness how advancements in technology and clinical protocols have expanded access and improved the effectiveness of extracorporeal support. What truly stands out is the passion and collaboration within the global ECLS community—no matter the location, professionals are united in their commitment to refining techniques, sharing knowledge, and continuously improving patient care.

Q: With your extensive clinical and product knowledge, what do you see as the future of ECLS, and how can Lifemotion contribute?

A: The future of ECLS is precision-driven, data-supported, and patient-centered. As technology evolves, we’re moving toward smarter, safer, and more efficient solutions that enhance clinical decision-making and patient management. Lifemotion is uniquely positioned to contribute by delivering high-quality service and repair solutions, supporting research initiatives, and fostering knowledge exchange. By strengthening our partnerships with healthcare professionals, we can help shape the next generation of extracorporeal therapies that improve both survival rates and quality of life.

Q: What do you enjoy doing outside of the ECLS world?

A: When I’m not immersed in all things ECLS, you’ll likely find me on the padel court—it’s my favorite way to stay active and recharge. I also run a small olive farm in Puglia, in the south of Italy, where we produce our own olive oil. It’s a completely different pace from the clinical world, but it keeps me grounded. There’s something incredibly rewarding about working with your hands and being connected to the land. It reminds me that whether it’s supporting life in the ICU or nurturing it in the soil, care and dedication make all the difference.

Q: Any final thoughts for the ECLS community?

A: My message to the ECLS community is simple: let’s stay connected, share knowledge, and keep pushing forward together. Collaboration and innovation are at the heart of what we do, and by working together, we can shape the future of ECLS and critical care. I look forward to meeting many of you at the upcoming EuroELSO Congress in Milan, 23-26 April 2025. Let’s continue to make a difference!

We’re thrilled to have Silvestro on board and look forward to the impact he’ll make at Lifemotion and within the broader ECLS community. Welcome, Silvestro!

The post Driving Innovation in ECLS: A Conversation with Silvestro Marinelli, Lifemotion’s New Global Product Manager appeared first on Lifemotion.